Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-07-05
2000-04-25
Eyler, Yvonne
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514617, 514619, 514456, 435 71, 435 723, A01N 4342, A01N 3718, A61K 3147, A61K 31165
Patent
active
060544678
ABSTRACT:
The present invention details methods for the treatment of cancer. In particular it concerns the induction of apoptosis in cancer cells following treatment with inhibitors of DNA repair in combination with p53. Treatment of glioblastoma and breast tumor cells with inhibitors of DNA repair induced growth suppression that was a result of p53-mediated apoptosis. Thus it appears that inhibitors of DNA repair in combination with p53 is involved in restoration of p53-mediated apoptosis.
REFERENCES:
patent: 5527676 (1996-06-01), Vogelstein et al.
patent: 5532220 (1996-07-01), Lee et al.
Gura. "Systems for identifying new drugs are often faulty" Science. vol. 278. pp. 1041-1042, Nov. 7, 1997.
Dermer. "Another Anniversary for the war on Cancer" Bio/Technology. vol. 12, p. 320, Mar. 12, 1994.
Wang et al "The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway" Genes and Dev. vol. 10 pp. 1219-1232, May 15, 1996.
Li et al, "Induction of apoptosis by b-lapachone in human prostate cancer cells" Cancer Res. vol. 55 No. 17, pp. 3712-3715, Sep. 1, 1995.
Del Bino et al, "Apoptotic cell death triggered by camptothecin or teniposide. The cell cycel specificity and effects of ionizing radiation" Cell Prolif. vol. 25, pp. 537-548, 1992.
Gotz et al, "p53: DNA damage, DNA repair, and apoptosis" Rev. Physiol. Biochem. Pharmacol. vol. 127, pp. 65-85, 1995.
Mi et al., "Base Excision Repari of 5-Hydroxymethyl-2'-Deoxyuridine (HMDURD) from DNA Induces High Molecular Weight DNA Double Strand Breaks and Apoptosis in Mammalian Fibroblasts Containing Mutant "P53, Proceed. Amer. Assoc. Cancer. Res., abstract 169, 37:24, Mar. 1996.
Venkatachalam et al., Modulation of DNA Damage Induced P53 Response in Human Cells, Proceed. of the Amer. Assoc. Cancer Res., abstract 951, 37:137, 1996.
Stierum et al., "Inhibition of Poly(ADP-Ribose) Polymerase Increases (+-)-Anti-Benzo (A) Pyrene Diolepoxide-Induced Micronuclei Formation and P53 Accumulation in Isolated Human Peripheral Blood Lymphocytes," Carcinogenesis, 16(11):2765-2771, 1995.
Fanjul et al., "A New Class of Retionoids With Selective Inhibition of AP-1 Inhibits Proliferation", Nature, 372(6501):107-111, 1994.
In: Dictionary of Natural Compounds, Volume One, Chapman and Hall, London, 1151, Entry C-01948, 1994.
In: Dictionary of Natural Compounds, Volume One, Chapman and Hall, London, 1151, Entry N-00835, 1994.
Lane, "P53, Guardian of the Genome," Nature, 358:15-16, 1992.
Rauchuang Ding et al., "Depletion of Poly(ADP-Ribose) Polymerase by Antisense RNA Expression Results in a Delay in DNA Strand Break Rejoining," J. Biol. Chem., 267(18):12804-12812, 1992.
International Search Report, NOv. 14, 1997 (INGN:032P--).
Adler et al., "UV Irradiation and Heat Shock Mediate JNK Activation via Alternate Pathways," Journal of Biological Chemistry, 270(44):26071-26077, 1995.
Ali-Osman et al., "Enhanced repair of a Cisplatin-Damaged Reporter Chloramphenicol-O-Acetyltransferase Gene and Altered Activities of DNA Polymerases .alpha.and .beta., and DNA Ligase in Cells of a Human Malignant Glioma Following In Vivo Cisplatin Therapy," Journal of Cellular Biochemistry, 54:11-19, 1994.
Baker et al., "Chromosome 17 Deletions and p53 Gene Mutations in Coloractal Carcinomas," Science, 244:217-221, Apr. 1989.
Baker et al., "p53 Gene Mutations Occur in Combination with 17p Allelic Deletions as Late Events in Colorectal tumorigenesis," Cancer Research, 50:7717-7722, Dec. 1990.
Baker et al., "Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53," Science, 249:912-915, 1990.
Baverstock and Will, "Evidence for the dominance of direct excitaiton of DNA in the formation of strand breaks in cells following irradiation," International Journal of Radiation Biology, 55(4): 563-568, 1989.
Bigner et al., "Cytogenetics of Human Brain Tumors," Cancer Genetic Cytogenetics, 47: 141-154, 1990.
Bigner et al., "Heterogenetity of Genotypic and Phenotypic Characteristics of Fifteen Permanent Cell Lines Derived from Human Gliomas," Journal of Neuropathology and Experimental Neurology, 40(3): 201-229, 1981.
Carter et al., "Adenovirus Containing a Deletion of the Early Region 2A Gene Allows Growth of Adeno-Associated Virus with Decreased Efficiency," Virology, 191:473-476, 1992.
Clarke et al., "Thymocyte apoptosis induced by p53-dependent and independent pathways," Nature, 362: 849-852, 1993.
Davidson et al., "A Model System for In Vivo Gene Transfer into the Central Nervous System Using an Adenoviral Vector," Nature Genetics, 3:219-223, Mar. 1993.
DiLeonardo et al., "DNA damage triggers a prolonged p53-dependent G .sub.1 arrest and long-term induction of Cip 1 in normal human fibroblasts," Genes and Development, 8: 2540-2551, 1994.
Diller et al., "p53 Functions as a Cell Cycle Control Protein is Osteosarcomas," Molecular and Cellular Biology, 10(11):57721-5781, Nov. 1990.
Donehower et al., "Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability," Genes and Development, 9: 882-895, 1995.
El-Deiry et al., "WAF1CIP1 Is Induced in p53-mediated G .sub.1 Arrest and Apoptosis," Cancer Research, 54: 1169-1174, 1994.
El-Diery et al., "WAF1, a Potential Mediator of p53 Tumor Suppression," Cell, 75: 817-825, 1993.
Eliyahu et al., "Meth A Fibrosarcoma Cells Express Two Transforming Mutant p53 Species," Oncogene, 3:313-321, 1988.
Eliyahu et al., "p53 -- A Potential Suppressor Gene?" Journal of Cellular Biochemistry, UCLA Symposia on Molecular & Cellular Biology, Abstracts, 19th Annual Meeting, Supplement 14C:264, Abstract No. I 030, Feb. 3-Mar. 11, 1990.
Eliyahu et al., "Wild-Type p53 Can Inhibit Oncogene-Mediated Focus Formation," Proc. Natl. Acad. Sci. USA, 86:8763-8767, Nov. 1989.
Evans et al., "Differential Sensitivity to the Induction of Apoptosis by Cisplatin in Proliferating and Quiescent Immature Rat Thymocytes Is Independent of the Levels of Drug Accumulation and DNA Adduct Formation," Cancer Research, 54: 1596-1603, 1994.
Fanjul et al., "A new class of retinoids with selective inhibition of AP-1 inhibits proliferation" Nature, 372: 107-111, 1994.
Finlay et al., "The p53 Proto-Oncogene Can Act as a Suppresor of Transformation," Cell, 1083-1093, Jun. 1989.
Fraval et al., "Increased Sensitivity of UV-Repair-Deficient Human Cells to DNA Bound Platinum Products Which Unlike Thymine Dimers Are Not Recognized by an Endomuclease Extracted From Micrococcus Luteus," Mutation Research, 51: 121-132, 1978.
Fujiwara et al., "Induction of Chemosensitivity in Human Lung Cancer Cells In Vivo by Adenovirus-mediated Transfer of the Wild-Type p53 Gene," Cancer Research, 54: 2287-2291, 1994.
Gebhardt et al., "A Tumor Suppressor Proto-Oncogene p53 Can Block Progression Through the Cell Cycle," Association of American Physicians, American Society for Clinical Investigation, American Federation for Clinical Research, Subspecialty Meetings, Sheraton Washington Hogel, Washington, D.C., May 6, 1990, Abstract.
Gipp et al., "DNA Damage Induced in HT-29 Colon Cancer Cells by Exposure to 1-Methyl-2-Nitrosoimidazole, A Reductive Metabolite of 1-Methyl-2-Nitroimidazole," Biochemical Pharmacology, 42 (Suppl): S127-S133, 1992.
Gjerset et al., "Use of Wild-Type p53 to Achieve Complete Treatment Sensitization of Tumor ells Expressing Endogenous Mutant p53," Molecular Carcinogenesis, 14:275-285, 1995.
Graham and Prevec, "Manipulation of Adenovirus Vectors," Methods in Molecular Biology, Gene Transfer and Expression Protocols, E.J. Murray (ed.), The Humana Press, Inc., vol. 7, Chapter 11, pp. 109-128, 1991.
Hinds et al., "Mutation is Required to Activate the p53 Gene for Cooperation with the ras Oncogene and Transformation," Journal of Virology, 63(2):739-746, Feb. 1989.
Hinds et al., "The p53 Proto-Oncogene Can Suppress Transformation by Other Oncogenes, and Mutations in the Proto-Oncogene Can Activate the Gene Transformation," Common Mechanisms of Transformation by Small DNA Tumor Viruses, Chapter 7, pp. 83-101, 1989.
Hinds, "Biological Consequences of Mutation of the p53 Proto-Oncogene," UMI Dissertation Services, Oct. 1989.
Huang et al., "Suppress
Eyler Yvonne
Sidney Kimmel Cancer Center
LandOfFree
Down-regulation of DNA repair to enhance sensitivity to P53-medi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Down-regulation of DNA repair to enhance sensitivity to P53-medi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Down-regulation of DNA repair to enhance sensitivity to P53-medi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-993627